Results 261 to 270 of about 122,145 (339)

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. [PDF]

PLoS Med
Chao AM, Gilden A, Wadden TA.
europepmc   +1 more source

The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. [PDF]

Int J Mol Sci
Chrysavgis L, Mourelatou NG, Koloutsou ME, Rozani S, Cholongitas E.   +4 more
europepmc   +1 more source

Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach

Internal Medicine Journal, EarlyView.
Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich, W. P. Abhayaratna, R. Audehm, E. I. Ekinci, R. J. MacIsaac, A. J. Nelson, A. Sharma, C. Pollock   +7 more
wiley   +1 more source

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis. [PDF]

Diabetes Ther
Elliott B, Tomlinson E, Desai N, Heald A, Field BC, Heiss C, Whyte MB.   +6 more
europepmc   +1 more source

The Risk of GLP‐1 Receptor Agonist (GLP‐1 RA) Exposure in Early Pregnancy. A Call to Action: Quantifying the Impact on Pregnancy Outcomes in the United Kingdom

Diabetes, Obesity and Metabolism, EarlyView.
Michael Stedman, Pensee Wu, Ian Halsall, Nadia Chaudhury, Barbara McGowan, Martin B. Whyte, Akheel Syed, Adrian Heald   +7 more
wiley   +1 more source

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? [PDF]

Biomolecules
Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, Tentolouris N.   +6 more
europepmc   +1 more source

Weight Loss in Primary Total Hip and Knee Arthroplasty: A Comparative Study of Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery. [PDF]

Arthroplast Today
Ledford CK, Mika AP, Lopez RJ, Spencer-Gardner LS, Hannon CP, Clarke HD, Abdel MP, Springer BD.   +7 more
europepmc   +1 more source

Signals arising from the gastrointestinal tract that affect food intake (Syömiseen vaikuttavat mahasuolikanavan signaalit) [PDF]

Purhonen, Anna-Kaisa
core  

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials. [PDF]

Life (Basel)
Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T, Jarosińska A, Siuda J, Holecki M.   +8 more
europepmc   +1 more source